Concetta Crivera
Overview
Explore the profile of Concetta Crivera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Peacock W, Coleman C, Wells P, Fermann G, Wang L, Baser O, et al.
J Health Econ Outcomes Res
. 2020 Jul;
6(3):160-173.
PMID: 32685588
Background: Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. Study...
12.
Wang L, Baser O, Wells P, Peacock W, Coleman C, Fermann G, et al.
J Health Econ Outcomes Res
. 2020 Jul;
6(2):84-94.
PMID: 32685582
Background: Increased hospital length of stay is an important cost driver in hospitalized low-risk pulmonary embolism (LRPE) patients, who benefit from abbreviated hospital stays. We sought to measure length-of-stay-associated predictors...
13.
Berger J, Haskell L, Ting W, Lurie F, Chang S, Mueller L, et al.
EPMA J
. 2020 Mar;
11(1):53-64.
PMID: 32140185
Background: Critical limb ischemia (CLI) is a severe stage of peripheral arterial disease and has a substantial disease and economic burden not only to patients and families, but also to...
14.
Khorana A, McCrae K, Milentijevic D, Laliberte F, Lejeune D, Crivera C, et al.
J Med Econ
. 2019 Dec;
23(4):323-329.
PMID: 31818164
Patients with cancer are at high risk for developing primary but also recurrent venous thromboembolism (VTE). This study examined healthcare utilization (HRU) and costs related to VTE recurrence among cancer...
15.
Outcomes associated with endovascular treatment among patients with acute ischemic stroke in the USA
Rai A, Crivera C, Kottenmeier E, Kalsekar I, Kumari R, Patino N, et al.
J Neurointerv Surg
. 2019 Oct;
12(4):422-426.
PMID: 31649206
Background: Few studies have examined the trends in clinical and economic outcomes of patients with acute ischemic stroke (AIS) who receive endovascular therapy (ET) in the real-world setting. Objective: To...
16.
Rai A, Crivera C, Kalsekar I, Kumari R, Patino N, Chekani F, et al.
Stroke
. 2019 May;
50(7):1902-1906.
PMID: 31104618
Background and Purpose- The purpose of this study was to evaluate trends in length of stay, discharge status, and costs among patients with acute ischemic stroke who underwent endovascular therapy...
17.
Khorana A, McCrae K, Milentijevic D, Fortier J, Nelson W, Laliberte F, et al.
Support Care Cancer
. 2019 Feb;
27(10):3833-3840.
PMID: 30734088
Purpose: Anticoagulant therapy for at least 3-6 months is currently recommended for treatment of venous thromboembolism (VTE) in patients with cancer, but the optimal duration of treatment is unknown. This...
18.
Wells P, Peacock W, Fermann G, Coleman C, Wang L, Baser O, et al.
J Thromb Thrombolysis
. 2019 Feb;
48(1):149-157.
PMID: 30729377
Introduction: Various risk stratification methods exist for patients with pulmonary embolism (PE). We used the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health...
19.
Datar M, Crivera C, Rozjabek H, Abbass I, Xu Y, Pasquale M, et al.
Am J Health Syst Pharm
. 2019 Jan;
76(5):275-285.
PMID: 30698654
Purpose: To compare patients with atrial fibrillation (AF) initiating direct oral anticoagulants (DOACs) versus warfarin on clinical outcomes including stroke, systemic embolism (SE), bleeding events, and cost of care. Methods:...
20.
Khorana A, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, et al.
Am J Hematol
. 2018 Nov;
94(2):E58-E61.
PMID: 30474161
No abstract available.